British company will test patch-type T cell COVID-19 vaccine
- Did Cloud Seeding Unleash a Deluge in Dubai?
- Scientists Identify Gut Bacteria and Metabolites that Lower Diabetes Risk
- OpenAI’s Model Matches Doctors in Assessing Eye Conditions
- UK: A Smoke-Free Generation by Banning Sales to Those Born After 2009
- Deadly Mutation: A New Monkeypox Variant Emerges in the DRC
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
British company will test patch-type T cell COVID-19 vaccine
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
British company will test patch-type T cell COVID-19 vaccine to to challenge mutated virus.
At present, the COVID-19 epidemic is still raging around the world, and the emergence of mutant strains of the COVID-19 has also brought new challenges to prevention and control.
Out of precautionary considerations, the iterative upgrade of the COVID-19 vaccine has become the focus of the global scientific community.
Emergex, a British vaccine manufacturer, has recently obtained a license from the Swiss drug regulatory authority.
It will start a phase 1 clinical trial of the second-generation COVID-19 vaccine in Lausanne, the capital of the Canton of Vaud, Switzerland on January 3 next year. A total of 26 vaccine volunteers will participate in the trial. Phased research results can be achieved in June next year.
According to the “Guardian” report on November 14, the second-generation COVID-19 vaccine that Emergex will test is a T-cell vaccine that can directly identify and kill infected cells, thereby achieving a longer-lasting immune effect.
The principle of the current vaccine is to induce human cells to produce antibodies to stop the virus.
This means that the effect of the vaccine may be weakened over time, so a booster shot is needed. But Emergex’s second-generation vaccine can activate human T cells to quickly kill target cells, thereby gaining immunity that may last for decades.
Even if the virus mutates, the performance of the T cell vaccine is even better.
In order to illustrate the advantages of T cell vaccines more vividly, Robin Cohen, Chief Commercial Officer of Emergex, used an asteroid impact as an analogy: “Virus invasion is like an asteroid impact.
After the virus code it carries is released, , T cells will soon be recognized as foreign invaders, and then the T cells will kill the infected cells before the new virus can be produced.”
For the test to be carried out in Switzerland, Cohen said: “This This is the first time that a regulatory authority has approved the implementation of a clinical trial of a T cell vaccine.”
The scientific community has previously recognized the power of T cells.
A study published in the journal Nature last week showed that after some people were infected with the new coronavirus, the T cells in the body immediately cleared the virus, leading to such people Obviously infected but showing negative nucleic acid test, this is the so-called “abortive infection” phenomenon.
In addition, T-cell vaccines are not a novel idea. A team at the University of Oxford has studied T-cell vaccines used to combat influenza for more than ten years.
Unlike the traditional injection method, Emergex’s T cell vaccine will be designed with a skin patch.
This patch is only the size of a nail and has a tiny needle on it, which can inject the vaccine into the human body within a few seconds.
The big advantage of this patch is that it can be stored at room temperature for up to 3 months, while existing vaccines need to be stored under refrigeration.
The first phase of the clinical trial will be carried out by Blaise Genton of the Basic Medical and Public Health Center of the University of Lausanne in Switzerland, but it will not be available to the public until 2025 at the earliest.
British company will test patch-type T cell COVID-19 vaccine to to challenge mutated virus.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
